参考文献/References:
［１］Cross D，Burmester JK．Gene therapy for cancer treatment ：past，present and future［J］．Clin Med Res，２００６，４：２１８－２２７．
［２］Roth JA．Adenovirus p５３gene therapy［J］．Expert Opin Biol Ther，２００６，６：５５－６１．
［３］Zhang S，Xu G，Liu C，et al．Clinical study of recombinant adenovirus p５３（Adp５３）combined with hyperthermia in advanced cancer（a report of１５cases）［J］．Int J Hyperthermia，２００５，２１：６３１－６３６．
［４］Van Dyke T．p５３and tumor suppression［J］．N Engl J Med，２００７，３５６：７９－８１．
［５］Levesque AA，Eastman A．p５３based cancer therapies：Is defective p５３the Achilles heel of the tumor［J］？Carcinogenesis，２００７，２８：１３－２０．
［６］Shen Y，Liu P，Zhang A，et al．Tumor microvasculature response to alternated cold and heat treatment ［J］．Conf Proc IEEE Eng Med Biol Soc，２００５，７：６７９７－６８００．
［７］Cepeda V，Fuertes MA，Castilla J，et al．Biochemical mechani－sms of cisplatin cytotoxicity［J］．Anticancer Agents Med Chem，２００７，７：３－１８．
［８］Eisold S，Linnebacher M，Ryschich E，et al．The effect of adeno－virus expressing wild type p５３on５fluorouracil chemose－nsitivity is related to p５３status in pancreatic cancer cell lines［J］．World J Gastroenterol，２００４，１０：３５８３－３５８９．
［９］Fabregat I，Roncero C，Fernandez M．Survival and apoptosis：a dysregulated balance in liver cancer［J］．Liver Int ，２００７，２７：１５５－１６２．
［１０］Atencio IA，Grace M，Bordens R，et al．Biological activities of a recombinant adenovirus p５３（SCH５８５００）administered by hepatic arterial infusion in a Phase１colorectal cancer trial［J］．Cancer Gene Ther，２００６，１３：１６９－１８１．
［１１］Pichla－Gollon SL，Drinker M，Zhou X，et al．Structure based identification of a major neutralizing site in an adenovirus hexon［J］．J Virol，２００７，８１：１６８０－１６８９．
［１２］Lutz W，Nowakowska－Swirta E．Gene p５３mutations，protein p５３，and anti－p５３antibodies as biomarkers of cancer process［J］．Int J Occup Med Environ Health，２００２，１５：２０９－２１８．
［１３］Yu ZW，Zhao P，Liu M，et al．Reversal of５flouroucial resis－tance by adenovirus mediated transfer of wild type p５３gene in multidrug resistant human colon carcinoma LoVo ／５FU cells［J］．World J Gastroenterol，２００４，１０：１９７９－１９８３．
［１４］Balint EE，Vousden KH．Activation and activities of the p５３tumour suppressor protein［J］．Br J Cancer，２００１，８５：１８１３－１８２３．
［１５］Vigano A，Dorgan M，Bruera E，et al．The relative accuracy of the clinical estimation of the duration of life for patients with end of life cancer［J］．Cancer，１９９９，８６：１７０－１７６．
［１６］Vigano A，Bruera E，Jhangri GS，et al．Clinical survival pre－dictors in patients with advanced cancer［J］．Arch Intern Med，２０００，１６０：８６１－８６８．
［１７］Fried TR，Bradley EH，Towle VR，et al．Understanding the treatment preferences of seriously ill patients［J］．N Engl J Med，２００２，３４６：１０６１－１０６６．
相似文献/References:
[1]沈海洋,杨光,刘瑞宝,等.肝右叶前、后段原发性肝癌动脉化疗栓塞术后近期疗效比较[J].介入放射学杂志,2010,(05):382.
SHEN Haiyang,YANG Guang,LIU Ruibao,et al.Short－term effects of TACE for primary hepatocellular carcinoma of the right hepatic lobe：a comparison between the lesions in anterior segments and the lesions in posterior segments[J].journal interventional radiology,2010,(11):382.
[2]张训,徐燕能,张向琼,等.CalliSpheres载药微球联合碘化油治疗大肝癌14例[J].介入放射学杂志,2020,29(01):39.
ZHANG Xun,XU Yanneng,ZHANG Xiangqiong,et al.CalliSpheres drug-eluting beads combined with lipiodol for TACE treatment of large liver cancer in 14 patients[J].journal interventional radiology,2020,29(11):39.
[3]李坤峰,郑 睿,胡章明.CalliSpheres载药栓塞微球加载表柔比星治疗不可切除原发性肝癌的疗效[J].介入放射学杂志,2023,32(02):131.
LI Kunfeng,ZHENG Rui,HU Zhangming..Clinical efficacy of CalliSpheres drug-eluting beads loaded with epirubicin in the treatment of unresectable primary liver cancer[J].journal interventional radiology,2023,32(11):131.
[4]顾萃华,潘仕文,邱 珏,等.基于MRI的放射组学模型预测中晚期肝癌患者TACE后肿瘤反应[J].介入放射学杂志,2024,33(01):63.
GU Cuihua,PAN Shiwen,QIU Jue,et al.Application of MRI-based radiomics model in predicting the tumor response in patients with advanced hepatocellular carcinoma after transcatheter arterial chemoembolization[J].journal interventional radiology,2024,33(11):63.